Skip to main content

Cardiome Pharma Corp. says it expects to pay $4.25 (U.S.) per share, the minimum price of a previously announced range, through a $27.5-million tender offer that expired Tuesday.

The drug development company had announced in August that it would pay between $4.25 and $5.10 per share to buy back between 6.47 million and 5.39 million of its common shares for a total of $27.5-million.

Cardiome used a modified Dutch auction procedure to determine the price.

Story continues below advertisement

According to preliminary results announced Wednesday, any shares tendered above $4.25 ($4.40 Canadian) won't be taken up by the company while any shares tendered at or below that price will be purchased for $4.25.

The price Cardiome will pay is below the Tuesday closing price of $4.80 (U.S.) at the Nasdaq stock market and $4.90 (Canadian) on the Toronto Stock Exchange. They closed at $4.59 on Aug. 25, the day the share buyback was announced.

The heart drug company said on Aug. 11, in its most recent quarterly report, it had a net loss of $1.4-million or 2 cents a share for the April-June period, narrowing last-year's loss for the same period of $18.1-million or 28 cents.

Cardiome's revenue soared to $8.6-million from $200,000, largely due to its agreement with Merck & Co., Inc., one of the world's largest pharmaceutical companies.



Report an error
Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨